Cardeus: Microglia blockade

Cardeus using COX-1 inhibitors to stabilize neurons in dementia

Astellas Pharma Inc. spinout Cardeus Pharmaceuticals Inc.'s COX-1 inhibitor tamps down neuroinflammation in the brain and could be synergistic with other treatments to keep dementia associated with diseases like Parkinson's in check.

Activation of microglial cells in the brain leads to neuroinflammation and neurodegeneration in Parkinson's disease (PD) and Huntington's disease (HD).

One pathway for activation of microglia is through the inflammatory stimulator prostaglandin E2. PGE2 levels in the brain are low, but can be increased through trauma, infection or the aggregation of

Read the full 816 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE